I. Polyakov

发表

A phase II study of picoplatin (pico) as second-line therapy for patients (pts) with small cell lung cancer (SCLC) who have resistant or refractory disease or have relapsed within 180 days of completing first-line, platinum (plat)-containing chemotherapy

O. Lipatov, J. Eckardt, H. Breitz, 2007 .

Hereditary Breast-Ovarian Cancer Syndrome in Russia

A. Sokolenko, E. Imyanitov, V. Semiglazov, 2010, Acta naturae.

Detection of EGFR mutations and EML4‐ALK rearrangements in lung adenocarcinomas using archived cytological slides

E. Imyanitov, A. Iyevleva, N. Mitiushkina, 2013, Cancer cytopathology.

Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer.

O. Lipatov, J. Eckardt, H. Breitz, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.